Ventricular rate control during atrial fibrillation and AV node modifications: Past, present, and future

PACE - Pacing and Clinical Electrophysiology

Volumn 27, Issue 3, 2004, Pages 382-393

  Zhang, Youhua ^a   Mazgalev, Todor N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Ablation; Atrial fibrillation; Atrioventricular node; Drugs; Rate control; Vagal nerve stimulation

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; MANNITOL; RECOMBINANT PROTEIN; TECADENOSON;

ARTIFICIAL HEART PACEMAKER; CALCIUM TRANSPORT; CARDIOVASCULAR PERFORMANCE; CATHETER ABLATION; ELECTROPHYSIOLOGY; GENE REPLACEMENT THERAPY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART INDEX; HEART PROTECTION; HEART RATE VARIABILITY; HEART RHYTHM; HEART VENTRICLE CONDUCTION; HEART VENTRICLE CONTRACTION; HIS BUNDLE; HISTOGRAM; HUMAN; PATHOPHYSIOLOGY; QRS COMPLEX; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; VAGUS NERVE STIMULATION; VAGUS TONE; WENCKEBACH PERIOD; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; HEART RATE; HUMANS; MYOCARDIAL CONTRACTION; VAGUS NERVE; VENTRICULAR FUNCTION;

EID: 1542715840     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2004.00447.x     Document Type: Review

References (117)

1. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84:469-481.
2. Philips ELS. Auricular fibrillation without other evidence of heart disease: A cause of reversible heart failure. Am J Med 1949; 7:478-489.
3. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563-570.
4. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570-1573.
5. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: Mechanisms and clinical implications. PACE 1996; 19:95-106.
6. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104:2118-2150.
7. Gillinov AM, McCarthy PM, Marrouche N, et al. Contemporary surgical treatment for atrial fibrillation. PACE 2003; 26:1641-1644.
8. Seshadri N, Marrouche NF, Wilber D, et al. Pulmonary vein isolation for treatment of atrial fibrillation: Recent updates. PACE 2003; 26:1636-1640.
9. Zipes DP. Specific Arrhythmias: Diagnosis and Treatment. In E Braunwald, (ed.): Heart disease A textbook of cardiovascular medicine. Philadelphia, PA, W.B. Saunders Company; 1992, pp. 667-715.
10. Wood DL, Hammill SC, Kopecky SL. Supraventricular arrhythmias. In ER Giuliani, BJ Gersh, MD McGoon, DL Hayes, HV Schaff, (eds.): Mayo Clinic Practice of Cardiology. St. Louis, MO, Mosby, 1996, pp. 748-779.
11. Liau CS, Chen MF, Lin FY, et al. Relationship between ventricular rate and cardiac output in mimic experimental atrial fibrillation. J Electrocardiol 1994; 27:163-168.
12. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990; 63:157-161.
13. Zhang Y, Mowrey KA, Zhuang S, et al. Optimal ventricular rate slowing during atrial fibrillation by feedback AV nodal-selective vagal stimulation. Am J Physiol 2002; 282:H1102-H1110.
14. Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol 1985; 5:35A-42A.
15. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304-310.
16. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44:1378-1382.
17. Klein HO, Pauzner H, Di Segni E, et al. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979; 139:747-749.
18. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J (Clin Res Ed) 1985; 290:9-11.
19. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990; 63:225-227.
20. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16:86-90.
21. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; And the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52-60.
22. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984; 108:1121-1127.
23. Hata T, Watanabe Y. Cellular Pharmacology of AV Nodal Conduction and Automaticity. In TN Mazgalev, PJ Tchou, (eds.): Atrial-AV Nodal Electrophysiology: A View From the millennium. Armonk, NY, Futura Publishing Company; 2000, pp. 121-131.
24. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142:498-501.
25. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38:2101-2113.
26. Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001; 3:437-440.
27. Channer KS, James MA, MacConnell T, et al. Beta-adrenoceptor blockers in atrial fibrillation: The importance of partial agonist activity. Br J Clin Pharmacol 1994; 37:53-57.
28. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594-598.
29. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98:2574-2579.
30. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30:791-798.
31. Roth A, Kaluski E, Felner S, et al. Clonidine for patients with rapid atrial fibrillation. Ann Intern Med 1992; 116:388-390.
32. Scardi S, Humar F, Pandullo C, et al. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 1993; 341:1211-1212.
33. Chiladakis JA, Stathopoulos C, Davlouros P, et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001; 79:287-291.
34. Lerman BB, Ellenbogen KA, Kadish A, et al. Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther 2001; 6:237-245.
35. Piot O, Chauvel C, Lazarus A, et al. Effects of a selective A1-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation. PACE 1998; 21:2459-2464.
36. Prystowsky EN, Niazi I, Curtis AB, et al. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003; 42:1098-1102.
37. Scheinman MM, Morady F. Nonpharmacological approaches to atrial fibrillation. Circulation 2001; 103:2120-2125.
38. Scheinman MM, Morady F, Hess DS, et al. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982; 248:851-855.
39. Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982; 306:194-200.
40. Huang SK, Bharati S, Graham AR, et al. Closed chest catheter desiccation of the atrioventricular junction using radiofrequency energy - a new method of catheter ablation. J Am Coll Cardiol 1987; 9:349-358.
41. Borggrefe M, Budde T, Podczeck A, et al. High frequency alternating current ablation of an accessory pathway in humans. J Am Coll Cardiol 1987; 10:576-582.
42. Morady F, Calkins H, Langberg JJ, et al. A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21:102-109.
43. Olgin JE, Scheinman MM. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21:557-564.
44. Feld GK. Polymorphic ventricular tachycardia complicating radiofrequency catheter modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Interv Card Electrophysiol 1997; 1:157-158.
45. Azar RR, Lippman N, Kluger J. Recurrent polymorphic ventricular tachycardia complicating radiofrequency catheter ablation of the atrioventricular junction. PACE 1998; 21:1837-1840.
46. Brembilla-Perrot B, Jacquemin L, Houplon P, et al. Bradycardia-induced polymorphic ventricular tachycardia after radiofrequency catheter modification of atrioventricular junction. J Interv Card Electrophysiol 1997; 1:153-155.
47. Peters RH, Wever EF, Hauer RN, et al. Bradycardia dependent QT prolongation and ventricular fibrillation following catheter ablation of the atrioventricular junction with radiofrequency energy. PACE 1994; 17:108-112.
48. Geelen P, Brugada J, Andries E, et al. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. PACE 1997; 20:343-348.
49. Darpo B, Walfridsson H, Aunes M, et al. Incidence of sudden death after radiofrequency ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol 1997; 80:1174-1177.
50. Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. PACE 1995; 18:1609-1614.
51. Ueng KC, Tsai TP, Tsai CF, et al. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 2001; 12:303-309.
52. Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: Effects of pacing mode and mode-switch algorithm. Circulation 1999; 99:1587-1592.
53. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. PACE 2000; 23:1020-1028.
54. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 1998; 2:121-135.
55. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78:1433-1436.
56. Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30:1039-1045.
57. Zhuang S, Zhang Y, Mowrey KA, et al. Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation 2002; 106:1853-1858.
58. Rosenqvist M, Bergfeldt L, Haga Y, et al. The effect of ventricular activation sequence on cardiac performance during pacing. PACE 1996; 19:1279-1286.
59. Leclercq C, Gras D, Le Helloco A, et al. Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing. Am Heart J 1995; 129:1133-1141.
60. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344:1043-1051.
61. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure: and chronic atrial fibrillation. A randomized, controlled study. Circulation 1998; 98:953-960.
62. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000; 101:1138-1144.
63. Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41:1697-1702.
64. Wittkampf FHM, De Jongste MJL, Lie HI, et al. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol 1988; 11:539-545.
65. Meijler FL, Jalife J. AV Node Function During Atrial Fibrillation. In TN Mazgalev, PJ Tchou, (eds.): Atrial-AV Nodal Electrophysiology: A View from the Millennium. Armonk, New York, Futura Publishing Company, 2000, pp. 251-268.
66. Moore EN. Observations on concealed conduction in atrial fibrillation. Circ Res 1967; 21:201-208.
67. Meijler FL, Jalife J, Beaumont J, et al. AV nodal function during atrial fibrillation: The role of electrotonic modulation of propagation. J Cardiovasc Electrophysiol 1996; 7:843-861.
68. Lau CP, Jiang ZY, Tang MO. Efficacy of ventricular rate stabilization by right ventricular pacing during atrial fibrillation. PACE 1998; 21:542-548.
69. Lau CP, Leung WH, Wong CK, et al. A new pacing method for rapid regularization and rate control in atrial fibrillation. Am J Cardiol 1990; 65:1198-1203.
70. Yamada H, Martin DO, Mowrey KA, et al. Effects of coupled pacing on cardiac performance during acute atrial tachycardia and fibrillation: An old therapy revisited for a new reason. Am J Physiol Heart Circ Physiol 2003; 285:H2630-H2638.
71. Kunze KP, Schluter M, Geiger M, et al. Modulation of atrioventricular nodal conduction using radiofrequency current. Am J Cardiol 1988; 61:657-658.
72. Duckeck W, Engelstein ED, Kuck KH. Radiofrequency current therapy in atrial tachyarrhythmias: Modulation versus ablation of atrioventricular nodal conduction. PACE 1993; 16:629-636.
73. Feld GK. Radiofrequency catheter ablation versus modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Cardiovasc Electrophysiol 1995; 6:217-228.
74. Fleck RP, Chen PS, Boyce K, et al. Radiofrequency modification of atrioventricular conduction by selective ablation of the low posterior septal right atrium in a patient with atrial fibrillation and a rapid ventricular response. PACE 1993; 16:377-381.
75. Feld GK, Fleck RP, Fujimura O, et al. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994; 90:2299-2307.
76. Williamson BD, Man KC, Daoud E, et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331:910-917.
77. Della Bella P, Carbucicchio C, Tondo C, et al. Modulation of atrioventricular conduction by ablation of the "slow" atrioventricular node pathway in patients with drug-refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25:39-46.
78. Morady F, Hasse C, Strickberger SA, et al. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 1997; 29:113-121.
79. Haissaguerre M, Gaita F, Fischer B, et al. Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. Circulation 1992; 85:2162-2175.
80. Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction. New Engl J Med 1992; 327:313-318.
81. Mitrani RD, Klein LS, Hackett FK, et al. Radiofrequency ablation for atrioventricular node reentrant tachycardia: Comparison between fast (anterior) and slow (posterior) pathway ablation. J Am Coll Cardiol 1993; 21:432-441.
82. Blanck Z, Dhala AA, Sra J, et al. Characterization of atrioventricular nodal behavior and ventricular response during atrial fibrillation before and after a selective slow-pathway ablation. Circulation 1995; 91:1086-1094.
83. Kreiner G, Heinz G, Siostrzonek P, et al. Effect of slow pathway ablation on ventricular rate during atrial fibrillation. Dependence on electrophysiological properties of the fast pathway. Circulation 1996; 93:277-283.
84. Fillette F, Fontaine G, Frank R, et al. Ventricular response in atrial fibrillation: Normal conduction, consequences of conduction disorders and preexcitation syndromes. Therapeutic implications. Ann Cardiol Angeiol (Paris) 1983; 32:7-19.
85. Olsson SB, Cai N, Dohnal M, et al. Noninvasive support for and characterization of multiple intranodal pathways in patients with mitral valve disease and atrial fibrillation. Eur Heart J 1986; 7:320-333.
86. Rokas S, Gaitanidou S, Chatzidou S, et al. A noninvasive method for the detection of dual atrioventricular node physiology in chronic atrial fibrillation. Am J Cardiol 1999; 84:1442-1445.
87. Tebbenjohanns J, Schumacher B, Korte T, et al. Bimodal RR interval distribution in chronic atrial fibrillation: impact of dual atrioventricular nodal physiology on long-term rate control after catheter ablation of the posterior atrionodal input. J Cardiovasc Electrophysiol 2000; 11:497-503.
88. Rokas S, Gaitanidou S, Chatzidou S, et al. Atrioventricular node modification in patients with chronic atrial fibrillation: Role of morphology of RR interval variation. Circulation 2001; 103:2942-2948.
89. Zhang Y, Bharati S, Mowrey KA, et al. His electrogram alternans reveal dual atrioventricular nodal pathway conduction during atrial fibrillation: The role of slow-pathway modification. Circulation 2003; 107:1059-1065.
90. Jazayeri MR, Sra JS, Deshpande SS, et al. Electrophysiologic spectrum of atrioventricular nodal behavior in patients with atrioventricular nodal reentrant tachycardia undergoing selective fast or slow pathway ablation. J Cardiovasc Electrophysiol 1993; 4:99-111.
91. Zhang Y, Bharati S, Mowrey KA, et al. His electrogram alternans reveal dual-wavefront inputs into and longitudinal dissociation within the bundle of His. Circulation 2001; 104:832-838.
92. Zhang Y, Mowrey K, Mazgalev T. Does RR interval distribution during atrial fibrillation indicate dual pathway atrioventricular nodal electrophysiology? (abstract) PACE 2003: 26[Part II], 1110.
93. Zhang Y, Zhuang S, Mowrey KA, et al. Demonstration of His electrogram alternans in vivo in dogs. (abstract) Circulation 2002; 106:II-179.
94. Maury P, Raczka F, Piot C, et al. QRS and cycle length alternans during paroxysmal supraventricular tachycardia: What is the mechanism? J Cardiovasc Electrophysiol 2002; 13:92-93.
95. Wallick DW, Zhang Y, Tabata T, et al. Selective AV nodal vagal stimulation improves hemodynamics during acute atrial fibrillation in dogs. Am J Physiol 2001; 281:H1490-H1497.
96. Imaizumi S, Mazgalev T, Dreifus LS, et al. Morphological and electrophysiological correlates of atrioventricular nodal response to increased vagal activity. Circulation 1990; 82:951-964.
97. Petrecca K, Shrier A. Spatial distribution of nerve processes and beta-adrenoreceptors in the rat atrioventricular node. J Anat 1998; 192:517-528.
98. Mazgalev T, Dreifus LS, Michelson EL, et al. Vagally induced hyperpolarization in atrioventricular node. Am J Physiol 1986; 251:H631-43.
99. Mazgalev TN, Garrigue S, Mowrey KA, et al. Autonomic modification of the atrioventricular node during atrial fibrillation: Role in the slowing of ventricular rate. Circulation 1999; 99:2806-2814.
100. Gatti PJ, Johnson TA, Phan P, et al. The physiological and anatomical demonstration of functionally selective parasympathetic ganglia located in discrete fat pads on the feline myocardium. J Auton Nerv Syst 1955; 51:255-259.
101. Lazzara R, Scherlag BJ, Robinson MJ, et al. Selective in situ parasympathetic control of the canine sinoatrial and atrioventricular nodes. Circ Res 1973; 32:393-401.
102. Ardell JL, Randall WC. Selective vagal innervation of sinoatrial and atrioventricular nodes in canine heart. Am J Physiol 1986, 251:H764-73.
103. Furukawa Y, Wallick DW, Carlson MD, et al. Cardiac electrical responses to vagal stimulation of fibers to discrete cardiac regions. Am J Physiol 1990; 258:H1112-H1118.
104. Randall WC, Rinkema LE, Jones SB. Local epicardial chemical ablation of vagal input to sinoatrial and atrioventricular regions of the canine heart. J Auton Nerv Syst 1984; 11:145-159.
105. Chiou CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad. Circulation 1997; 95:2573-2584.
106. Zhang Y, Zhuang S, Yamada H, et al. First successful demonstration of vagally controlled ventricular rate during AF in chronically instrumented dogs. (abstract) PACE 2002; 25:583.
107. Carlson MD, Geha AS, Hsu J, et al. Selective stimulation of parasympathetic nerve fibers to the human sinoatrial node. Circulation 1992; 85:1311-1317.
108. Keim S, Mazgalev T, Tchou P. Physiologic effects of subthreshold burst stimulation on the human AV node (abstract). PACE 1993; 16:158.
109. Quan KJ, van Hare GF, Biblo LA, et al. Endocardial stimulation of efferent parasympathetic nerves to the atrioventricular node in humans: Optimal stimulation sites and the effects of digoxin. J Interv Card Electrophysiol 2001; 5:145-152.
110. Quan KJ, Lee JH, van Hare GF, et al. Identification and characterization of atrioventricular parasympathetic innervation in humans. J Cardiovasc Electrophysiol 2002; 13:735-739.
111. Schauerte P, Mischke K, Plisiene J, et al. Catheter stimulation of cardiac parasympathetic nerves in humans: A novel approach to the cardiac autonomic nervous system. Circulation 2001; 104:2430-2435.
112. Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 2000; 6:1395-1398.
113. Lurie KG, Loy A, Dutton J, et al. Measurement of extracellular space in the rabbit AV node. J Histochem Cytochem 1991; 39:1671-1677.
114. Lurie KG, Sugiyama A, McKnite S, et al. Modulation of AV nodal and Hisian conduction by changes in extracellular space. Am J Physiol 1999; 276:H953-H960.
115. Chiba S, Suzuki Y, Hashimoto K. Atrial fibrillation induced by infusion of hypertonic solutions into the canine sinus node artery in situ. J Pharmacol Exp Ther 1969; 167:274-281.
116. Gaudesius G, Miragoli M, Thomas SP, et al. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res 2003; 93:421-428.
117. Zipes DP. The Atrioventricular Node: A Riddle Wrapped in a Mystery Inside an Enigma. In TN Mazgalev, PJ Tchou, (eds.): Atrial-AV Nodal Electrophysiology: A View from the Millennium. Armonk, NY, Futura Publishing Company, 2000 pp. xi-xiv.